ADAPTIVE SUPPORT ENVIRONMENT FOR ALCOHOL DEPENDENCE

酗酒的社会代价是巨大的；估计为 每年近1000亿美元。一种治疗酒精中毒的有效方法 用药物进行心理社会治疗。不幸的是，仍有很高的 治疗中途辍学率和服药依从性受限。 该项目名为酒精依赖适应性支持环境(ASEAD)，旨在 在酒精治疗的早期阶段通过提供 在两次治疗之间的高危时期为患者提供支持。 ASEAD不会取代标准疗法，但它是通过以下方式加强治疗的工具 24小时为患者提供实时帮助。支持被定向 成功治疗的两个重要因素是更好的药物治疗 坚持和加强心理社会支持。病人，在诊所就诊的间隙， 携带可提供交互平台的电信设备 治疗性干预。这些干预措施适应了发展中国家不断变化的需求 有耐心的。该系统由数据录入模板、算法数据库组成 和消息，以及分析和通信软件。改进了 依从性或治疗保留率将对 临床试验和治疗护理均取得成功。阶段1创建了一个正在运行的 用一个主题样本对该系统进行原型和测试。第二阶段将增强 并通过随机对照试验对其进行评价。 建议的商业应用： 每年有超过50万人寻求酒精治疗。NIAAA目前资助20 药物治疗的踪迹。不遵守和故态复萌的代价是非常昂贵的 为降低成本的创新提供有吸引力的目标。Talaria，Inc.预计 授权该系统用于临床试验和临床护理。其他市场包括哮喘和 减肥。

The societal costs of alcoholism are substantial; estimated at almost $100 billion each year. An effective approach to alcoholism combines psychosocial therapy with medications. Unfortunately there remains a high drop-out rate from therapy and limited compliance with medication regiments. This project, Adaptive Support Environment for Alcohol Dependence (ASEAD), aims to reduce relapse in the early stages of alcohol treatment by providing patients with support during the high risk periods between therapy sessions. ASEAD does not replace standard therapy but is a tool to enhance therapy by providing patients assistance in real-time, 24 hours a day. Support is directed at two important components of successful treatment, better medication adherence and enhanced psychosocial support. Patients, between clinic visits, carry telecommunications devices that provide an interactive platform for therapeutic interventions. The interventions adapt to the changing needs of the patient. The system consists of data entry templates, databases of algorithms and messages, and analysis and communication software. Improvements in adherence or treatment retention rates will have a significant impact on the success of both clinical trials and therapeutic care. Phase 1 creates a working prototype and tests the system with a sample of subjects. Phase 2 will enhance the system and evaluate it through a randomized controlled trial. PROPOSED COMMERCIAL APPLICATION: Over 500,000 people/year seek alcohol treatment. The NIAAA currently funds 20 pharmacotherapy trails. The price of noncompliance and relapse is very expensive and provides and attractive target for innovations that reduce costs. Talaria, Inc. anticipates licensing this system for clinical trials and clinical care. Other markets include asthma and weight reduction.